PubMed:8106150 JSONTXT

{"project":"bc5cdr-valid-experiment","denotations":[{"id":"T1","span":{"begin":35,"end":41},"obj":"Chemical"},{"id":"T2","span":{"begin":50,"end":61},"obj":"Disease"},{"id":"T3","span":{"begin":65,"end":69},"obj":"Chemical"},{"id":"T4","span":{"begin":124,"end":136},"obj":"Disease"},{"id":"T5","span":{"begin":152,"end":156},"obj":"Chemical"},{"id":"T6","span":{"begin":198,"end":216},"obj":"Chemical"},{"id":"T7","span":{"begin":346,"end":356},"obj":"Disease"},{"id":"T8","span":{"begin":426,"end":434},"obj":"Chemical"},{"id":"T9","span":{"begin":472,"end":478},"obj":"Chemical"},{"id":"T10","span":{"begin":493,"end":503},"obj":"Disease"},{"id":"T11","span":{"begin":558,"end":567},"obj":"Chemical"},{"id":"T12","span":{"begin":569,"end":582},"obj":"Chemical"},{"id":"T13","span":{"begin":584,"end":596},"obj":"Chemical"},{"id":"T14","span":{"begin":598,"end":604},"obj":"Chemical"},{"id":"T15","span":{"begin":606,"end":617},"obj":"Chemical"},{"id":"T16","span":{"begin":623,"end":629},"obj":"Chemical"},{"id":"T17","span":{"begin":652,"end":662},"obj":"Disease"},{"id":"T18","span":{"begin":704,"end":716},"obj":"Disease"},{"id":"T19","span":{"begin":742,"end":751},"obj":"Chemical"},{"id":"T20","span":{"begin":756,"end":766},"obj":"Chemical"},{"id":"T21","span":{"begin":793,"end":803},"obj":"Disease"},{"id":"T22","span":{"begin":815,"end":823},"obj":"Chemical"},{"id":"T23","span":{"begin":869,"end":877},"obj":"Disease"},{"id":"T24","span":{"begin":886,"end":896},"obj":"Disease"},{"id":"T25","span":{"begin":898,"end":906},"obj":"Chemical"},{"id":"T26","span":{"begin":921,"end":929},"obj":"Disease"},{"id":"T27","span":{"begin":945,"end":951},"obj":"Disease"}],"text":"Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.\nA group of four monkeys was rendered parkinsonian with the toxin MPTP. They were then treated chronically with L-DOPA/benserazide 50/12.5 mg/kg given orally daily for 2 months. This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia. A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified. Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology. However, yohimbine and meperidine reduced predominantly the dyskinetic movements. Baclofen was also useful in one monkey against a more dystonic form of dyskinesia. Atropine converted the dystonic movements into chorea."}